Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook

Beta Bionics Inc. (NASDAQ:BBNX) is one of the best hot stocks to invest in. On October 1, Goldman Sachs upgraded Beta Bionics to Buy from Neutral with a price target of $26, which was upgraded from $18. Goldman Sachs’ analysis of the diabetes technology market shows sustained growth and profitability for Beta Bionics.

Earlier in the second quarter of 2025, Beta Bionics saw a significant 54% year-over-year increase in net sales, reaching $23.2 million. This growth was mirrored in patient adoption, with a 57% increase in new patient starts, totaling 4,934 new patients adopting the islet system. Concurrently, the gross margin showed an improvement to 53.8%.

To boost market reach, the company expanded its sales force by 20 territories. Reflecting this performance and optimism, Beta Bionics raised its full-year 2025 net sales guidance to between $88 million and $93 million, up from the previous forecast of $82 million to $87 million.

Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company that designs, develops, and commercializes solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

While we acknowledge the potential of BBNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.